Keywords: Breast Neoplasms, Diagnosis, Radionuclide Imaging, Radiopharmaceuticals, Antineoplastic Agent, Epirubicin, Etoposide, Glycoprotein P, Methoxy Isobutyl Isonitrile Technetium Tc 99m, Mitomycin C, Protein Bcl 2, Tracer, Apoptosis, Breast Cancer, Cancer Chemotherapy, Cancer Diagnosis, Cancer Radiotherapy, Clinical Trial, Drug Clearance, Drug Response, Drug Uptake, Functional Assessment, Human, Lung Cancer, Lymphoma, Meta Analysis, Multidrug Resistance, Phenotype, Prediction, Prognosis, Protein Expression, Protein Interaction, Review, Sarcoma, Scintiscanning, Metabolic Clearance Rate, Technetium Tc 99m Sestamibi, Treatment Outcome,
Affiliations: *** IBB - CNR ***
Center for Nuclear Medicine, Consiglio Nazionale dell Ricerche, Federico II University, Via S. Pansini 5, 80131 Naples, Italy
Dept. of Biomorphol. and Funct. Sci., Federico II University, Via S. Pansini 5, 80131 Naples, Italy
References: Not available.
MIBI as prognostic factor in breast cancer
Evaluation of treatment response is of primary importance in the management of patients with cancer. Both positron- and γ-emitting compounds have been used to monitor changes in tumor metabolism or viability after therapy. The use of 99mTc-labeled lipophilic cations raised the possibility to predict the tumor response to treatment and to identify patients who will become refractory to subsequent therapy. In particular, many studies have shown the prognostic value of 99mTc-MIBI scan in different types of malignancy including breast and lung cancer, lymphoma and sarcoma. The ability of 99mTc-MIBI to interact with P-glycoprotein, allowing the functional assessment of the multidrug resistant phenotype, is one of the mechanisms underlying its prognostic value. Additional mechanisms of cell resistance, mainly involving alterations of apoptosis, may affect 99mTc-MIBI uptake in tumors. Therefore, either an enhanced tracer clearance or a reduced early uptake of 99mTc-MIBI indicate a poor response to therapy. In both cases, 99mTc-MIBI scan may ensure that the further management strategy will be effective in individual cancer patients.
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(361 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote